Cargando…
Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular Dystrophy
We assessed the potential of Lmna-mRNA repair by spliceosome-mediated RNA trans-splicing as a therapeutic approach for LMNA-related congenital muscular dystrophy. This gene therapy strategy leads to reduction of mutated transcript expression for the benefit of corresponding wild-type (WT) transcript...
Autores principales: | Azibani, Feriel, Brull, Astrid, Arandel, Ludovic, Beuvin, Maud, Nelson, Isabelle, Jollet, Arnaud, Ziat, Esma, Prudhon, Bernard, Benkhelifa-Ziyyat, Sofia, Bitoun, Marc, Lorain, Stéphanie, Bonne, Gisèle, Bertrand, Anne T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862133/ https://www.ncbi.nlm.nih.gov/pubmed/29499949 http://dx.doi.org/10.1016/j.omtn.2017.12.012 |
Ejemplares similares
-
Lamin A/C Assembly Defects in LMNA-Congenital Muscular Dystrophy Is Responsible for the Increased Severity of the Disease Compared with Emery–Dreifuss Muscular Dystrophy
por: Bertrand, Anne T., et al.
Publicado: (2020) -
Gene Therapy for LMNA-related Congenital Muscular Dystrophy (L-CMD) by Trans-Splicing
por: Azibani, Feriel, et al.
Publicado: (2015) -
Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing
por: Trochet, Delphine, et al.
Publicado: (2016) -
Allele‐specific silencing therapy for Dynamin 2‐related dominant centronuclear myopathy
por: Trochet, Delphine, et al.
Publicado: (2017) -
Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy
por: Trochet, Delphine, et al.
Publicado: (2022)